Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Solana Company ( (HSDT) ) just unveiled an update.
On April 8, 2026, Solana Company and its Chief Medical Officer, Antonella Favit-Van Pelt, MD, PhD, mutually agreed to her resignation and separation from the company, effective the same day. The move marks a significant leadership change in the company’s medical oversight and could affect how it manages clinical programs and strategic healthcare initiatives going forward.
Under a separation agreement effective April 8, 2026, Solana Company will pay Dr. Favit-Van Pelt a lump-sum separation payment of $875,000, less applicable withholdings, within ten business days of that date. In return, she has waived and released employment-related claims and agreed to continue honoring confidentiality and invention assignment obligations, providing the company with legal clarity and protection of its proprietary information after her departure.
The most recent analyst rating on (HSDT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Solana Company stock, see the HSDT Stock Forecast page.
Spark’s Take on HSDT Stock
According to Spark, TipRanks’ AI Analyst, HSDT is a Neutral.
The score is held back primarily by weak financial quality (large losses and persistent cash burn) and bearish technicals (below major moving averages with negative MACD). Offsetting factors include a low-debt balance sheet with a strengthened equity base, and a mixed-but-constructive earnings call pointing to operational progress and yield initiatives, plus a positive leadership hire.
To see Spark’s full report on HSDT stock, click here.
More about Solana Company
Solana Company operates in the healthcare and biopharmaceutical sector, where it relies on executive medical leadership to guide clinical strategy, regulatory alignment, and development of its therapeutic programs. The role of a chief medical officer is central to shaping the company’s research priorities and overall medical governance within its market focus.
Average Trading Volume: 449,578
Technical Sentiment Signal: Strong Sell
Current Market Cap: $104M
See more data about HSDT stock on TipRanks’ Stock Analysis page.